Get the Stockscreener App
0.00
100.00%
-2.38
After Hours:
2.34
2.34
+
Overview
News
Price History
Option Chain
Financials
Why SAVA Down?
Discussions
Forecast
Stock Split
Dividend History
Cassava Sciences Inc stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -100.00% over the past month.
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia. It has one business segment: the development of novel drugs and diagnostics.
See More
Previous Close:
$2.38
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$114.97M
Revenue:
-
Net Income/Loss:
$-97.22M
P/E Ratio:
0.00
EPS:
-1.38
Net Cash Flow:
$-82.44M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$0.00
52-Week Range:
$0.00
$4.98
Cassava Sciences Inc Stock (SAVA) Company Profile
Name
Cassava Sciences Inc
Sector
Industry
Phone
512-501-2444
Address
6801 N CAPITAL OF TEXAS HIGHWAY, AUSTIN, TX
Compare SAVA vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SAVA
Cassava Sciences Inc
|
0.00 | 114.97M | 0 | -97.22M | -82.44M | -1.38 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Cassava Sciences Inc Stock (SAVA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-26-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Oct-08-24 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jul-01-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Nov-16-22 | Downgrade | B. Riley Securities | Buy → Neutral |
| Jul-15-21 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jul-07-21 | Reiterated | Maxim Group | Buy |
| Apr-27-21 | Initiated | B. Riley Securities | Buy |
| Feb-16-21 | Reiterated | H.C. Wainwright | Buy |
| Oct-23-20 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-23-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| May-18-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| May-15-20 | Downgrade | Maxim Group | Buy → Hold |
| Jan-10-20 | Reiterated | Maxim Group | Buy |
View All
Cassava Sciences Inc Stock (SAVA) Latest News
Cassava Sciences Inc (SAVA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Cassava Sciences Inc (SAVA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Cassava Sciences Inc (SAVA) Institutional Confidence - TradingKey
Cassava Sciences Inc (SAVA) Valuation: PE, PB & Fair Value Analysis - TradingKey
Cassava Sciences Inc (SAVA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Cassava Sciences Inc (SAVA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Cassava Sciences Inc (SAVA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Cassava Sciences Inc (SAVA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Cassava Sciences Inc (SAVA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Cassava Sciences Says DOJ Has Closed Probe Into Allegations Around Its Alzheimer’s Program - Stocktwits
The Gross Law Firm Reminds Cassava Sciences, Inc. Investors of t - GuruFocus
Cassava Sciences (FLNA) Insider Trading Activity 2026 $FLNA - MarketBeat
Cassava Sciences (FLNA) Institutional Ownership 2026 $FLNA - MarketBeat
Top Cassava Sciences (FLNA) Competitors 2026 - MarketBeat
Cassava Sciences stock (US14428V1035): pressure grows as short interest stays elevated after ticker - AD HOC NEWS
Cassava Sciences (FLNA) Short Interest & Short Float | Updated May 2026 $FLNA - MarketBeat
Cassava Sciences stock (US14428V1035): Clinical progress in Alzheimer's treatments - AD HOC NEWS
TradingKey - TradingKey
Cassava Sciences (NASDAQ:FLNA) Posts Earnings Results - MarketBeat
Cassava Sciences stock (US14428V1035): Alzheimer drug candidate in focus after latest data update - AD HOC NEWS
FLNA Stock Price and Chart — NASDAQ:FLNA - TradingView
Cassava Sciences | 8-K: Current report - Moomoo
Filana Therapeutics Presents TSC-Related Epilepsy Program at Eilat XVIII - Yahoo Finance
FLNA Stock Price, Quote & Chart | FILANA THERAPEUTICS INC (NASDAQ:FLNA) - ChartMill
Cassava Sciences says DOJ has closed probe into allegations around its Alzheimer’s program - MSN
Filana Therapeutics (FLNA) details 2026 meeting and equity plan vote - Stock Titan
Cassava Sciences (FLNA) Financials 2026Income Statement and Balance Sheet $FLNA - MarketBeat
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of February 10, 2025 in Cassava Sciences, Inc. LawsuitSAVA - ACCESS Newswire
Cassava Sciences (FLNA) Stock Chart and Price History 2026 $FLNA - MarketBeat
Cassava Sciences (FLNA) 10K Form and Latest SEC Filings 2026 - MarketBeat
Cassava Sciences (FLNA) Stock Trends and Sentiment 2026 $FLNA - MarketBeat
Cassava Sciences (FLNA) Earnings Date and Reports 2026 $FLNA - MarketBeat
Cassava Sciences (FLNA) Options Chain & Prices 2026 $FLNA - MarketBeat
Cassava Sciences (FLNA) FDA Approvals, PDUFA Dates & Drug Alerts 2026 $FLNA - MarketBeat
Cassava Sciences (FLNA) Stock Forecast and Price Target 2026 $FLNA - MarketBeat
Cassava Sciences (FLNA) Stock Price, News & Analysis $FLNA - MarketBeat
Cassava Sciences (NASDAQ:SAVA) Stock Price Down 0.6%Should You Sell? - MarketBeat
SAVA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Cassava Sciences, Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
FLNA Stock Price, News & Analysis - Stock Titan
Filana Therapeutics Announces Publication in Epilepsia of Preclinical Simufilam Data - GlobeNewswire
Death Cross: What are the future prospects of Cassava Sciences Inc Equity WarrantPortfolio Gains Summary & Verified Chart Pattern Trade Signals - baoquankhu1.vn
FLNA|Cassava Sciences Ord Shs|Price:1.440|Chg%:0.06 - TradingKey
FLNA|Cassava Sciences Ord Shs|Price:1.440|Chg%:-0.12 - TradingKey
If You Invested $1,000 in Cassava Sciences (SAVA) - Stock Titan
Trend Report: What is the dividend yield of Cassava Sciences Inc Equity Warrant2026 Geopolitical Influence & Entry and Exit Point Strategies - baoquankhu1.vn
Aug Chart Watch: Is Cassava Sciences Inc Equity Warrant trading at a discountWeekly Market Outlook & High Accuracy Swing Trade Signals - baoquankhu1.vn
Market Leaders: Can Cassava Sciences Inc Equity Warrant maintain its current growth rate2026 Levels & Low Risk Investment Opportunities - baoquankhu1.vn
Aug Update: Is Cassava Sciences Inc Equity Warrant subject to activist investor interestWatch List & Consistent Return Investment Signals - baoquankhu1.vn
RSI Check: What is the dividend yield of Cassava Sciences IncPortfolio Performance Report & High Conviction Buy Zone Alerts - baoquankhu1.vn
SEC Moves To Set Up $40M Investor Fund In Cassava Case - Law360
Cassava Sciences Inc Stock (SAVA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Cassava Sciences Inc Stock (SAVA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Barry Richard | President & CEO |
Nov 20 '25 |
Buy |
2.76 |
150,000 |
414,000 |
938,060 |
| Barry Richard | President & CEO |
Nov 19 '25 |
Buy |
2.75 |
73,385 |
201,809 |
788,060 |
| Cook Robert Christopher | Chief Operating & Legal Office |
Sep 30 '25 |
Buy |
2.91 |
13,725 |
39,940 |
13,725 |
| Barry Richard | President & CEO |
Sep 22 '25 |
Buy |
2.28 |
7,172 |
16,352 |
714,675 |
| Barry Richard | President & CEO |
Sep 18 '25 |
Buy |
2.24 |
190,633 |
426,424 |
660,195 |
| Barry Richard | President & CEO |
Sep 19 '25 |
Buy |
2.29 |
47,308 |
108,319 |
707,503 |
0.74%
1.44%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):